VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
evogliptin
Preclinical
Small molecule
D
Dong-A ST Co., Ltd.
1
Indications
17
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Calcific Aortic Valve Disease
Terminated
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Calcific Aortic Valve Disease
Preclinical
Terminated
Clinical
Trials by Indication
[1]
Type 2 Diabetes
3 trials
Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Completed
·
D
Dong-A ST Co., Ltd.
·
Phase 3
·
NCT04356742
·
198 enrolled
Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
Completed
·
D
Dong-A ST Co., Ltd.
·
Phase 3
·
NCT04170998
·
283 enrolled
Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)
Completed
·
D
Dong-A ST Co., Ltd.
·
Phase 4
·
NCT02974504
·
207 enrolled
Efficacy and Safety
2 trials
A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin
Completed
·
D
Dong-A ST Co., Ltd.
·
Phase 3
·
NCT02946541
·
160 enrolled
Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes
Completed
·
D
Dong-A ST Co., Ltd.
·
Phase 3
·
NCT02949193
·
222 enrolled
Clinical Trial
2 trials
A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin
Unknown status
·
K
Kyung Hee University Hospital at Gangdong
·
Phase 4
·
NCT04706637
·
120 enrolled
A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg
Unknown status
·
D
Dong-A ST Co., Ltd.
·
Phase 4
·
NCT04653779
·
54 enrolled
Function
1 trial
Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction
Completed
·
D
Dong-A ST Co., Ltd.
·
Phase 1
·
NCT02754219
·
24 enrolled
Renal insufficiency
1 trial
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency
Completed
·
S
Samsung Medical Center
·
Phase 2
·
NCT03667300
·
209 enrolled
8 more indications
Randomized
1 trial
Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD
Unknown status
·
—
·
Phase 4
·
NCT04521452
·
218 enrolled
Observational Study
1 trial
Observational Study to Evaluate the Efficacy and Safety of Suganon Tab. or Sugamet XR Tab.
Unknown status
·
D
Dong-A ST Co., Ltd.
·
·
NCT04326166
·
1,971 enrolled
Metabolism
1 trial
Effect of Evogliptin on Bone Metabolism in Human
Unknown status
·
—
·
Phase 4
·
NCT02587975
·
20 enrolled
Dialysis Patients
1 trial
The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients
Completed
·
D
Dong-A ST Co., Ltd.
·
Phase 1
·
NCT04195919
·
17 enrolled
Chronic Hepatitis
1 trial
Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes
Unknown status
·
S
Seung Up Kim
·
Phase 4
·
NCT05473806
·
28 enrolled
Type 2 Diabetes Mellitus
1 trial
Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)
Completed
·
E
Eurofarma Laboratorios S.A.
·
Phase 2
·
NCT02689362
·
146 enrolled
Non-Alcoholic Fatty Liver Disease
1 trial
Efficacy and Safety of Evoglitin in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver Diseases
Completed
·
D
Dong-A ST Co., Ltd.
·
Phase 4
·
NCT03910361
·
51 enrolled
Calcific Aortic Valve Disease
1 trial
An Adaptive Phase 2/3 Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel, 2 Arm Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)
Terminated
·
R
REDNVIA Co., Ltd.
·
Preclinical
·
NCT05143177
·
486 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
17 trial records for evogliptin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
evogliptin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for evogliptin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Dong-A ST Co., Ltd. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Preclinical
[1]
Company
D
Dong-A ST Co., Ltd.
Related News